Phoenix Molecular Designs
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8755 Ash St Suite 1, Vancouver, British ...Phone Number
(604) 674-1796Website
www.phoenixmd.caRevenue
<$5 MillionIndustry
About Phoenix Molecular Designs
Phoenix Molecular Designs is a Vancouver-based biotechnology company founded by Dr. Sandra Dunn, focusing on the development of targeted small molecule drugs for treating Triple Negative Breast Cancer. The company aims to create safer and more effective therapies that improve patient outcomes by targeting RSK, a key driver in tumor growth and metastasis. Their innovative approach to precision medicine seeks to enhance the quality of life for cancer patients who have limited treatment options. Phoenix Molecular Designs is currently advancing its drug pipeline, including a Phase 2 clinical trial for its lead candidate.Explore more
Phoenix Molecular Designs Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Phoenix Molecular Designs
Compare insights from companies similar to Phoenix Molecular Designs, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Phoenix Molecular Designs Tech Stack
A closer look at the technologies used by Phoenix Molecular Designs
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Phoenix Molecular Designs
Sign Up For FreeTo access detailed company insights
Phoenix Molecular Designs is a Vancouver-based biotechnology company founded by Dr. Sandra Dunn, focusing on the development of targeted small molecule drugs for treating Triple Negative Breast Cancer. The company aims to create safer and more effective therapies that improve patient outcomes by targeting RSK, a key driver in tumor growth and metas... Read More
